Xeris Biopharma stock holds at $8.48 after earnings miss
Published on 08/31/2026 at 14:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Xeris Biopharma Holdings, Inc. (US98422E1038) stock traded at $8.48 on August 31, 2026, after the company posted second-quarter earnings of -$0.18 a share and revenue of $92.10 million on August 6, 2026.
The market cap stood at $1.55 billion, and the shares were up against a 12-month range of $5.25 to $10.08 as investors weighed a $0.19 EPS miss versus consensus.
Earnings set the tone
According to the Xeris Biopharma trading note, the company reported -$0.18 in EPS for the quarter ended August 6, 2026, against expectations for $0.01, while revenue reached $92.10 million versus $90.12 million forecast.
That gap matters because it combines a 100 percent-plus earnings shortfall with a revenue beat of $1.98 million, leaving the earnings line weaker than the top line.
Targets moved higher
The same report said Barclays lifted its price objective to $12.00 from $9.00 and kept an overweight view, while the average price target shown there also stood at $12.00.
On the same session, that target sat 41.0 percent above the $8.48 quote, a spread that shows how far the stock still trades below the latest consensus level.
The report also said Wall Street Zen cut the name to buy and Weiss Ratings moved it to sell, showing a split that matches the stock's mixed post-earnings read.
Gvoke remains central
Xeris still leans on Gvoke, its ready-to-use liquid glucagon product for severe hypoglycemia, alongside a broader endocrine and orphan-disease portfolio.
That mix matters for investors because a commercial product with recurring prescriptions can offset the heavier development spending typical for biopharma names.
Price and valuation
Xeris Biopharma stock closed at $8.48 on August 31, 2026, with a market cap of $1.55 billion and a 12-month range of $5.25 to $10.08.
For now, the share price sits 15.9 percent below the 12-month high of $10.08 and 61.3 percent above the 12-month low of $5.25.
More on Xeris Biopharma stock
Company: Xeris Biopharma Holdings, Inc.
ISIN: US98422E1038
Ticker: XERS
Exchange: NASDAQ
Price (as of August 31, 2026): $8.48 USD
Market cap: $1.55 billion (as of August 31, 2026)
Sector / Industry: Health Care / Biotechnology
Index membership: Russell 2000
